Achieve CFO granted 180,000 stock options

Achieve Life Sciences Chief Financial Officer granted 180,000 stock options.

Rhea-AI Filing Summary

Achieve Life Sciences Chief Financial Officer granted 180,000 stock options. The Form 4 reports that CFO Mark K. Oki received a stock option to buy 180,000 shares of common stock at an exercise price of $4.36 per share.

The option vests as to one quarter of the total award on the first anniversary of January 28, 2026, then in substantially equal monthly installments over the following 36 months, as long as he continues providing service to the company on each vesting date.

Insider Trade Summary

Grant/Award: 180,000 shares

Grant/Award 1 txn

Insider Oki Mark K

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	180,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 180,000 contracts (Direct)

Footnotes (1)

1. F1. The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Achieve Life Sciences (ACHV) disclose in this Form 4?

Achieve Life Sciences disclosed a grant of stock options to its Chief Financial Officer, Mark K. Oki. He received options for 180,000 shares of common stock, documenting an equity-based component of his executive compensation and aligning incentives with long-term shareholder value.

How many stock options did ACHV CFO Mark Oki receive?

CFO Mark K. Oki received a stock option covering 180,000 shares of Achieve Life Sciences common stock. This grant represents an equity incentive that can be exercised in the future, subject to the specified vesting schedule and his continued service with the company over time.

What is the exercise price of the ACHV stock options granted to the CFO?

The stock options granted to ACHV CFO Mark K. Oki have an exercise price of $4.36 per share. This means he can purchase Achieve Life Sciences common stock at $4.36 once the options vest, potentially benefiting if the market price exceeds that level.

When do the new Achieve Life Sciences CFO options start vesting?

The options start vesting on the first anniversary of January 28, 2026, when one quarter of the 180,000-share award vests. The remaining shares then vest in substantially equal monthly installments over 36 months, conditioned on his continued service to Achieve Life Sciences.

How long will it take for the ACHV CFO’s stock options to fully vest?

The options vest over a total period of four years. One quarter vests on the first anniversary of January 28, 2026, and the remaining three quarters vest in substantially equal monthly installments over the next 36 months, assuming continuous service throughout that timeframe.

What is the expiration date of the new ACHV stock options?

The stock option granted to Achieve Life Sciences CFO Mark K. Oki expires on January 28, 2036. If unexercised by that date, the right to purchase the 180,000 underlying shares at the $4.36 exercise price will lapse and become void.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:09 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oki Mark K

(Last) (First) (Middle)

22722 29TH DR SE

SUITE 100

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	01/28/2026		A		180,000		(1)	01/28/2036	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	Sandra Thomson as attorney-in-fact for Mark Oki	01/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.